Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Preferred Stock Liabilities (2023 - 2024)

Upstream Bio has reported Preferred Stock Liabilities over the past 2 years, most recently at $380.9 million for Q3 2024.

  • Quarterly results put Preferred Stock Liabilities at $380.9 million for Q3 2024, up 64.93% from a year ago — trailing twelve months through Sep 2024 was $380.9 million (up 64.93% YoY), and the annual figure for FY2023 was $230.9 million, changed.
  • Preferred Stock Liabilities for Q3 2024 was $380.9 million at Upstream Bio, roughly flat from $380.9 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for UPB hit a ceiling of $380.9 million in Q2 2024 and a floor of $230.9 million in Q3 2023.